Age Does Not Worsen the Efficacy Nor Tolerance to Combined Induction Therapies in Locally Advanced Non-small Cell Lung Cancer

作者：Marquez Medina Diego^*; Martin Marco Antonio; Ojanguren Garranz Amaia

来源：Anticancer Research, 2014, 34(8): 4373-4376.

• Chemoradiation
• chemotherapy
• elderly patients
• induction treatment
• locally advanced
• non-small cell lung cancer

Background: One third of non-small cell lung cancer (NSCLC) affects elderly patients in a locally advanced (LA) stage. Induction therapy followed by a curative approach is becoming the standard-of-care for LA-NSCLC. Patients and Methods: We compared the efficacy and tolerance to induction chemotherapy or chemo-radiation followed by surgery or definitive radiotherapy in patients younger (N=64) and older (N=44) than 70 years with LA-NSCLC. Results: Elderly patients trended towards having a worse baseline performance status, and presented a higher percentage of IIIB, and squamous tumors. Nevertheless, no significant differences in response rate, operability, or disease-free and overall survival were found between age groups in the whole series, nor in the sub-group of resected patients. Grade 3-4 toxicity tended to be lower in elderly patients. Conclusion: Age by itself did not significantly worsen either the efficacy or tolerance to combined induction and definitive treatment in patients with LA-NSCLC and Eastern Cooperative Oncology Group performance status 0-2.

• 出版日期2014-8